Novartis Ag (NVSEF) Change in Working Capital (2009 - 2026)

Novartis Ag has disclosed Change in Working Capital across 16 years of filings, most recently posting -$787.0 million for Q1 2026.

• Change in Working Capital for Q1 2026 came in at -$787.0 million, down 3647.62% year-over-year; the trailing twelve-month figure through Mar 2026 was $955.0 million (down 24.33% YoY), and the FY2025 annual result was -$26.0 million, up 96.32% from the prior year.
• Change in Working Capital came in at -$787.0 million for Q1 2026 at Novartis Ag, down from -$36.0 million in the prior quarter.
• In the past five years, Change in Working Capital ranged from a high of $1.7 billion in Q3 2023 to a low of -$787.0 million in Q1 2026.
• The 5-year median for Change in Working Capital is $5.0 million (2024), against an average of $256.1 million.
• Across the five-year window, Change in Working Capital soared 3157.14% in 2022 and slumped 3647.62% in 2026, its largest moves.
• Novartis Ag's Change in Working Capital stood at $456.0 million in 2022, then sank by 184.21% to -$384.0 million in 2023, then soared by 101.3% to $5.0 million in 2024, then sank by 820.0% to -$36.0 million in 2025, then tumbled by 2086.11% to -$787.0 million in 2026.
• The last three Change in Working Capital figures came in at -$787.0 million (Q1 2026), -$36.0 million (Q4 2025), and $1.3 billion (Q3 2025), per Business Quant data.